These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31807859)

  • 21. Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma.
    Gurion R; Bernstine H; Domachevsky L; Michelson C; Raanani P; Vidal L; Shochat T; Gafter-Gvili A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):687-691. PubMed ID: 30017596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL.
    Lim SH; Hyun SH; Kim HS; Lee JY; Yoo KH; Jung KS; Song HN; Cho J; Park S; Ko YH; Kim SJ; Choi JY; Kim WS
    Bone Marrow Transplant; 2016 Jun; 51(6):807-12. PubMed ID: 26855154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
    Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
    Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
    Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
    Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
    Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
    Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
    J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
    Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
    Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
    Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
    Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma.
    Jiang C; Su M; Kosik RO; Zou L; Jiang M; Tian R
    Clin Nucl Med; 2015 Oct; 40(10):767-73. PubMed ID: 26164182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of [
    Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Winter A; Rybicki L; Shah SN; Jagadeesh D; Gerds AT; Hamilton BK; Liu H; Dean R; Sobecks R; Pohlman B; Smith M; Kalaycio M; Bolwell BJ; Majhail NS; Hill BT
    Leuk Lymphoma; 2018 May; 59(5):1195-1201. PubMed ID: 28853617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.
    Loirat M; Chevallier P; Leux C; Moreau A; Bossard C; Guillaume T; Gastinne T; Delaunay J; Blin N; Mahé B; Dubruille V; Augeul-Meunier K; Peterlin P; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Mohty M; Moreau P; Le Gouill S
    Ann Oncol; 2015 Feb; 26(2):386-92. PubMed ID: 25392158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of
    Ying Z; Mi L; Zhou N; Wang X; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J
    Chin J Cancer Res; 2019 Feb; 31(1):162-170. PubMed ID: 30996574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.
    Yhim HY; Park Y; Han YH; Kim S; Kang SR; Moon JH; Jeong JH; Shin HJ; Kim K; Choi YS; Kim K; Kim MK; Kong E; Kim DS; Eo JS; Lee JH; Kang DY; Lee WS; Lee SM; Do YR; Ham JS; Kim SJ; Kim WS; Choi JY; Yang DH; Kwak JY
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2274-2284. PubMed ID: 30056546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim 18F-FDG PET/CT and BCL2 for predicting the prognosis of patients with diffuse large B-cell lymphoma in the rituximab era.
    Jiang M; Chen P; Ruan X; Xu W; Li T; Wu L; Zhou W; Wu H; Wang Q
    Nucl Med Commun; 2018 Feb; 39(2):147-153. PubMed ID: 29189488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.